BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17119113)

  • 1. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.
    Perrine SP; Hermine O; Small T; Suarez F; O'Reilly R; Boulad F; Fingeroth J; Askin M; Levy A; Mentzer SJ; Di Nicola M; Gianni AM; Klein C; Horwitz S; Faller DV
    Blood; 2007 Mar; 109(6):2571-8. PubMed ID: 17119113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.
    Faller DV; Mentzer SJ; Perrine SP
    Curr Opin Oncol; 2001 Sep; 13(5):360-7. PubMed ID: 11555713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
    Mentzer SJ; Fingeroth J; Reilly JJ; Perrine SP; Faller DV
    Blood Cells Mol Dis; 1998 Jun; 24(2):114-23. PubMed ID: 9628848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
    Ghosh SK; Forman LW; Akinsheye I; Perrine SP; Faller DV
    Blood Cells Mol Dis; 2007; 38(1):57-65. PubMed ID: 17161633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma.
    Ghez D; Damotte D; Perrine SP; Faller DV; Canioni D; Brousse N; Lefrère F; Varet B; Hermine O
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):417-9. PubMed ID: 16640822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
    Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
    Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations.
    Oertel SH; Riess H
    Recent Results Cancer Res; 2002; 159():89-95. PubMed ID: 11785848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
    Jones K; Nourse J; Corbett G; Gandhi MK
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e169-74. PubMed ID: 19196381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bibliography. Current World Literature. Cancer in AIDS.
    Curr Opin Oncol; 2001 Sep; 13(5):B139-42. PubMed ID: 11560153
    [No Abstract]   [Full Text] [Related]  

  • 11. Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells.
    He Y; Cai S; Zhang G; Li X; Pan L; Du J
    Virus Res; 2008 Jul; 135(1):175-80. PubMed ID: 18455826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
    Ghosh SK; Perrine SP; Williams RM; Faller DV
    Blood; 2012 Jan; 119(4):1008-17. PubMed ID: 22160379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of treatment with intravenous ganciclovir on Epstein-Barr virus viremia demonstrated after pediatric liver transplantation.
    Østensen AB; Sanengen T; Holter E; Line PD; Almaas R
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
    Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
    Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
    Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
    Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
    Haverkos B; Alpdogan O; Baiocchi R; Brammer JE; Feldman TA; Capra M; Brem EA; Nair S; Scheinberg P; Pereira J; Shune L; Joffe E; Young P; Spruill S; Katkov A; McRae R; Royston I; Faller DV; Rojkjaer L; Porcu P
    Blood Adv; 2023 Oct; 7(20):6339-6350. PubMed ID: 37530631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral response to chemotherapy in endemic burkitt lymphoma.
    Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
    Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.